Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trenmix is an injectable anabolic-androgenic steroid (AAS) blend developed by DEK Pharma, typically containing a combination of three trenbolone esters: trenbolone acetate, trenbolone hexahydrobenzylcarbonate, and trenbolone enanthate. This formulation is designed to provide a multi-stage release profile, offering both rapid onset and prolonged activity of the potent androgen trenbolone. Trenbolone acts as a high-affinity agonist of the androgen receptor, significantly enhancing protein synthesis, nitrogen retention, and muscle mass while exhibiting strong anti-catabolic effects by antagonizing glucocorticoid receptors. While trenbolone derivatives are used in veterinary medicine to increase livestock efficiency, Trenmix is primarily marketed for physique and performance enhancement and is not approved for human therapeutic use by major regulatory agencies like the FDA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Trenmix.